RespireRx Pharmaceuticals (OTCQB:RSPI) Inc Interim CEO Arnold Lippa tells Proactive it has filed a provisional patent application for a novel lipid-based formulation technology (LFT).
Lippa says it may be used to improve the solubility and bioavailability of poorly soluble drugs, particularly cannabinoids.